Literature DB >> 25470200

Fatty liver disease: the liver labyrinth.

Branwen Morgan.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25470200     DOI： 10.1038/516S8a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  4 in total

1.  A liver-selective LXR inverse agonist that suppresses hepatic steatosis.

Authors:  Kristine Griffett; Laura A Solt; Bahaa El-Dien M El-Gendy; Theodore M Kamenecka; Thomas P Burris
Journal:  ACS Chem Biol       Date:  2012-12-27       Impact factor: 5.100

2.  ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development.

Authors:  Hayato Nakagawa; Atsushi Umemura; Koji Taniguchi; Joan Font-Burgada; Debanjan Dhar; Hisanobu Ogata; Zhenyu Zhong; Mark A Valasek; Ekihiro Seki; Juan Hidalgo; Kazuhiko Koike; Randal J Kaufman; Michael Karin
Journal:  Cancer Cell       Date:  2014-08-14       Impact factor: 31.743

Review 3.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

Review 4.  The genetics of NAFLD.

Authors:  Quentin M Anstee; Christopher P Day
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-24       Impact factor: 46.802
  4 in total
  3 in total

1.  HEPATOKIN1 is a biochemistry-based model of liver metabolism for applications in medicine and pharmacology.

Authors:  Nikolaus Berndt; Sascha Bulik; Iwona Wallach; Tilo Wünsch; Matthias König; Martin Stockmann; David Meierhofer; Hermann-Georg Holzhütter
Journal:  Nat Commun       Date:  2018-06-19       Impact factor: 14.919

2.  No Evidence for a Causal Link between Serum Uric Acid and Nonalcoholic Fatty Liver Disease from the Dongfeng-Tongji Cohort Study.

Authors:  Yuhan Tang; Yanyan Xu; Peiyi Liu; Cheng Liu; Rong Zhong; Xiao Yu; Lin Xiao; Min Du; Ling Yang; Jing Yuan; Youjie Wang; Weihong Chen; Sheng Wei; Yuan Liang; Xiaomin Zhang; Tangchun Wu; Meian He; Xiaoping Miao; Ping Yao
Journal:  Oxid Med Cell Longev       Date:  2022-03-15       Impact factor: 6.543

3.  Sitagliptin Is More Effective Than Gliclazide in Preventing  Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease.

Authors:  Jing Ren; Xiaoyu Wang; Christine Yee; Mark D Gorrell; Susan V McLennan; Stephen M Twigg
Journal:  Molecules       Date:  2022-01-22       Impact factor: 4.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.